Objective. Angiotensin-converting enzyme (ACE) inhibitors have been shown to lower central augmentation index (cAI), an index of arterial wave reflection, more than β-blockers.We tested whether this is also true for long-term treatment with an angiotensin receptor blocker (ARB). Methods. One-hundred and fifty-six subjects with essential hypertension were randomised to treatment with either irbesartan or atenolol. cAI and central blood pressure (BP) were determined by pulse wave analysis from the radial and the carotid artery after six and after 18 months treatment. Results. Peripheral and central systolic and diastolic BP were reduced to a similar extent in the two groups. cAI was reduced with irbesartan, but increased with atenolol (derived from the carotid artery: -6±10 vs. -4±12% after six months, p<0.001; -4±12 vs. +1±11% after 18 months; p=0.011). Furthermore, central to peripheral pulse pressure (PP) amplification was unaffected by treatment with irbesartan, but decreased with atenolol.
Introduction
Although it has been known for several years that central haemodynamic effects differ substantially between various antihypertensive agents, 1,2 the importance of these central effects has only recently been appreciated. A practical reason for increasing interest also lies in the recent availability of non-invasive methods for the assessment of central haemodynamics, such as provided by pulse wave analysis. 3, 4 In conjunction with conventional measurement of peripheral blood pressure (BP) for calibration, central systolic blood pressure (SBP) and diastolic blood pressure (DBP) can be derived from the arterial waveform of a peripheral artery, such as the radial artery, by use of a mathematical transfer function. 3, 4 In addition, this method also provides the opportunity to study the level of augmentation of central SBP, or the central augmentation index (cAI), caused by reflection of pulse waves in the periphery. Increased pulse wave velocity from stiff large arteries and increased peripheral vascular resistance are two major causes for an earlier return, and a higher amplitude of the reflected pulse wave, respectively. Earlier return of the reflected pulse wave shifts central BP augmentation from diastole into late systole, and therefore leads to augmentation of central SBP and hence cardiac afterload. In addition to detrimental effects on the heart, elevated central SBP is also thought to be a major determinant of the risk for stroke and indeed several studies have already confirmed an independent predictive value of cAI. 5, 6 To derive cAI, recording of a more proximal arterial waveform, such as from the carotid artery, has recently been shown to be more accurate compared with the recording from the rather distal radial artery. 7 However, because correct recording from the carotid artery is more difficult and time-consuming, most studies have been limited to recordings from the radial artery.
In the two largest, prospective antihypertensive treatment studies employing this new technology, combination therapy including an angiotensinconverting enzyme (ACE)-inhibitor has been shown to have superior effects on central systolic BP and cAI compared to β-blockers. 8, 9 In addition, therapy with an ACE-inhibitor preserved the central to peripheral amplification of pulse pressure (PP), whereas atenolol reduced this natural amplification. This is important, as the disappearance of PP amplification has been shown to independently predict cardiovascular mortality. 10 Overall, these unfavourable effects of β-blockers on haemodynamics are at least partly responsible for the recent questioning of their role as first-line therapeutic agents in essential hypertension. [11] [12] [13] Whether treatment with an angiotensin receptor blocker (ARB) has similar long-term beneficial effects on haemodynamics in patients with essential hypertension as ACE-inhibitors has not been studied. We therefore examined the effects of irbesartan versus atenolol on peripheral and central haemodynamics by pulse wave analysis doi:10.3317/jraas.2008.003
from both the radial and the carotid artery in a long-term trial over 18 months. 
Methods

Design
Trial participants
Males and females between 25 and 65 years of age, with a SBP of 150-200 mmHg and/or a DB) of 95-115 mmHg were eligible. Subjects were excluded for known or suspected secondary hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular disease, renovascular disease, insulin-dependent diabetes mellitus, uncontrolled non-insulindependent diabetes mellitus, history of intolerance to atenolol, irbesartan, hydrochlorothiazide or amlodipine and pre-treatment with an ACEinhibitor or an ARB within the last six months.
Measurement of arterial wave reflection and central BP
To derive the central arterial waveform, a validated system (Sphygmocor™; AtCor Medical, Sydney, Australia) was used that employs highfidelity applanation tonometry (Millar) for noninvasive registration of peripheral arterial pressure waves and appropriate computer software for pressure wave analysis (Sphygmocor™). 3, 4 Pressure calibration was accomplished through automatically, non-invasively obtained supine BP of the brachial artery of the dominant arm after a 30-minute rest (Dinamap Compact T; Johnson & Johnson Medical Ltd, Newport, UK). BP was measured five times over 10 minutes and the mean of the last three measurements were taken for calibration.
Pressure wave recording was then performed at the radial artery of the same arm with the wrist gently hyperextended. The pressure wave was averaged from single pressure waves recorded consecutively for eight seconds. Averaged pressure waves were accepted only if variation of peak and bottom pressures of single pressure waves was < 5%. The central pressure wave was then automatically synthesised from the radial pressures by a built-in generalised transfer function. In addition, pressure wave measurement was also performed at the right carotid artery as it has been suggested that cAI may be more accurately derived from this vascular site. 7, 14, 15 Prior to analysis, a visual check for correct detection of inflection points was performed in each radial and central pressure wave by an independent blinded investigator. From the derived central waveforms, data is given on central systolic and diastolic BP, time to the first shoulder determined by the outgoing pressure wave (cP 1 ), time to the second shoulder determined by the reflected pressure wave (cP 2 ), either absolutely or as percent of ejection duration (ED), as well as augmentation pressure (AP) as the pressure height difference between cP 2 -cP 1 , and cAI defined as: (pressure difference between cP 2 -cP 1 )/pulse pressure. In addition, central to peripheral differences of SBP and PP as indices of SBP and PP amplification are given both in absolute terms, and as ratios (peripheral SBP/central SBP and peripheral PP/central PP).
Statistics
All statistical analyses were carried out using SPSS-software (release 15.0, SPSS Inc., Chicago, IL, USA). Based on a previous study, 16 a sample size of at least 70 patients in each treatment group was needed to detect a 5% change of cAI, as the primary end point of the study, with an estimated standard deviation of 12%, given a twosided p-value of 0.05 at a power of 90%. Taking a maximum drop-out rate of 20% over the course of 18 months into account, 84 patients were randomised to each group. Normal distribution of data was confirmed by the Kolmogorov-Smirnov test before further analysis. Normally distributed clinical baseline data were compared by unpaired student t-tests. Duration of hypertension, age, glucose and high-density lipoprotein (HDL) cholesterol identified as not-normally distributed data were compared by Mann-Whitney-U tests. Gender distribution between treatment groups was compared by Fisher's exact test. Analysis of variance (ANOVA) was used to compare the data obtained by pulse wave analysis between treatment groups. In addition, ANOVA was used to compare data obtained during therapy to baseline data. If ANOVA comparison indicated a significant difference, the Bonferroni method was applied for subsequent paired comparisons between data from six months versus baseline and 18 months versus baseline, respectively. Multivariate analysis of variance (MANOVA) based on the general linear model was used to determine the impact of concomitant therapy with hydrochlorothiazide and amlodipine as covariates on the effects of irbesartan versus atenolol treatment as a fixed 
factor on all major outcome variables. Two-tailed p-values < 0.05 were considered statistically significant. Data in the text and in the tables are given as mean±standard deviation.
Results
From 168 patients with essential hypertension initially randomised, 156 patients completed the study. Forty-five percent of patients in the irbesartan and 41% in the atenolol group had never received any prior antihypertensive medication, and no patient had ever received ACE-inhibitor or ARB treatment. Moving from the local area was stated as the main reason for not completing the study. The subsequent analysis is based on the 75 patients in the irbesartan and 81 patients in the atenolol group completing the study, although intention-to-treat analysis gave similar results (not shown). Table 1 gives the baseline clinical characteristics of patients randomised to either irbesartan or atenolol. Brachial SBP and DBP and all other recorded clinical parameters were similar between the two groups at baseline. Only 22% of patients in the irbesartan and 28% in the atenolol group required additional hydrochlorothiazide, and only 4% and 6% additional amlodipine treatment. With irbesartan, heart rate did not change after six and after 18 months (-0.3±8.9 and -1.6±9.9; n.s.), whereas atenolol led to a decrease of heart rate after six and after 18 months compared to baseline (-9.1±10.2 and -7.0±10.3, respectively, both p<0.001). Table 2 gives the results of the pulse wave analysis from the radial artery. Radial SBP and DBP were reduced to a similar degree in the two treatment groups. Central SBP and DBP derived from the radial artery by generalised transfer function were also reduced to a similar extent with irbesartan and atenolol. ED was prolonged by treatment with atenolol only, and was strongly correlated with the decrease in heart rate (r=-0.76, p<0.001 after six months and r=-0.80, p<0.001 after 18 months). Although the absolute time to the reflected wave (cP 2 in ms) was prolonged with atenolol, when normalised for ED, timing of the reflected wave was similar in the two treatment groups (cP 2 in % of ED).
Normalising for ED also revealed a slightly earlier timing of the outgoing pressure wave when patients were being treated with atenolol for six months. There were no differences in terms of the height of the outgoing pressure wave (cP1 height) during the course of the study. Augmentation pressure (cAP) and in particular augmentation index (cAI) were disparately affected in the two treatment arms after six and after 18 months: irbesartan decreased cAI after 18 months whereas, atenolol increased cAI after six months. There was a correlation between the decrease in heart rate and the increase of cAI in the atenolol group (r=-0.59, p<0.001 after six months and r=-0.67, p<0.001 after 18 months).
In table 3, the results of the pulse wave analysis from the carotid artery are given. Again, the reductions in carotid SBP and DBP and in the derived central SBP and DBP were similar between the two treatment groups. Similar to the measurements from the radial artery, there were no differences in timing of outgoing and reflected pressure waves when normalised to changes in ejection duration. Again, cAP was reduced only with irbesartan while cAI at baseline was higher in the atenolol group. This was most likely due to small, non-significant differences in baseline heart rate (table 1), because of the correlations between heart rate and augmentation index at baseline (r=-0.49, p<0.001 in the atenolol group, r=-0.31, p<0.001 in the irbesartan group). During treatment, cAI was reduced in the irbesartan group after six and after 18 months, but increased in the atenolol group after six months compared to baseline.
In 
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patients treated with atenolol. Similarly, PP amplification and its ratio decreased only in the atenolol, but not in the irbesartan group. Concomitant treatment with hydrochlorothiazide or amlodipine had no significant effect on any major outcome variables (e.g. ΔSBP-Amp 18 months: p=0.027 irbesartan vs. atenolol, with hydrochlorothiazide and amlodipine treatment entered as covariates into MANOVA).
Discussion ACE-inhibitors have recently been shown to have more beneficial effects on central SBP, cAI and central to peripheral PP amplification compared to β-blockers, [8] [9] but the long-term effects of ARB treatment on these parameters have not been studied so far. In the current study we could show that long-term treatment with irbesartan has beneficial effects on cAI and that PP amplification can be preserved with irbesartan but not with β-blocker treatment. These effects of ARB treatment may have contributed to their superiority demonstrated in the Losartan for End point Reduction (LIFE) trial. 17 So far only one other study has directly compared the effects of an ARB against those of a β-blocker on these parameters, 18 although beneficial effects of ARB treatment on cAI had already been demonstrated in different contexts. 16, 19 In this smaller study in 21 patients with essential hypertension over a duration of six weeks, treatment with eprosartan led to a greater decrease of central SBP and a decrease of cAI, whereas atenolol led to an increase of cAI. These beneficial effects of eprosartan on central haemodynamics were achieved despite a lesser decrease of pulse wave velocity, as an index of large artery stiffness, although studies have shown that arterial wave reflection can be affected independently from pulse wave velocity. 20 Although we could not detect significant differences in central SBP lowering in the irbesartan versus the atenolol group, we can confirm in a larger number of patients and over a long treatment duration of 18 months that treatment with an ARB lowers cAI. In contrast to previous studies, cAI was also derived from the waveform of the carotid artery, which has been shown to be more accurate than using the waveform of the radial artery. 7, 14, 15 Numerous effects of ARB treatment have been demonstrated that may account for this beneficial effect on wave reflection, including effects on vascular function 21 and structure. 22 These effects might be mediated by reduction of angiotensin II type 1 receptor activation and/or increased angiotensin II type 2 receptor activation, although a role for increased angiotensin (1-7) levels during ARB treatment has also been suggested more recently. 23, 24 Our data also confirm that treatment with atenolol leads to a significant increase in cAI. 9, 18 The decrease in heart rate during β-blocker therapy has been shown to contribute substantially to the increase in cAI by increasing systolic ejection duration, 25 and also in our study, heart rate was strongly correlated with cAI at baseline and during active therapy. However, the timing of the reflected wave was not substantially altered by atenolol when normalised to ejection duration. This indicates that the lesser reduction of cAI with atenolol may at least in part be due to lesser lowering of the intensity of wave reflection compared to treatment with an ARB. A likely explanation for this would be the lack of vasodilatory properties of atenolol. It has also been shown that these unfavourable haemodynamic effects of atenolol lead to an increase of brain natriuretic peptide, as a marker of cardiac afterload. 26, 27 The role of β-blockers has been questioned recently, [11] [12] [13] and the new British guidelines for the treatment of hypertension have even removed these agents now from the list of first-line agents (http://www.nice.org.uk/CG034). However, most of the evidence against β-blockers is derived from studies with atenolol. 11, 13 Newer β-blockers, such as nebivolol, which has additional vasodilatory properties, may have more favourable effects on haemodynamics, and might be more suitable for the treatment of hypertension. Key: cAI = central augmentation index; CAP = central augmentation pressure; cDBP = central diastolic blood pressure; cP1 = central pressure height 1 ; cP2 = central pressure height 2; cSBP = central systolic blood pressure; ED = ejection duration; rDBP = radial diastolic blood pressure; rSBP = radial systolic blood pressure; * = p<0.05, ** = p<0.01, *** = p<0.001 compared to baseline by Bonferroni post-hoc test; Δ = respective changes from baseline. 
Interestingly, although the changes of cAI from baseline were still significantly different between irbesartan and atenolol after 18 months, when directly comparing cAI at 18 months there was no difference, regardless of whether cAI was derived from the radial or the carotid artery. This seemed to be based on an attenuation of the detrimental effects of atenolol on cAI after 18 months. The physiological basis for this observation is currently unclear. It is conceivable that long-term treatment with atenolol may affect vascular structure and/or function indirectly via effects on cardiac output or via lowering of BP, although previous studies have not been able to demonstrate a reduction of total peripheral vascular resistance after one year of treatment with atenolol. 29 Additionally, the decrease of heart rate with atenolol was numerically less after 18 months compared to after six months (-9.1±10.2 versus -7.0±10.3 bpm; p=0.01 by ANOVA), and this might have attenuated the effect of atenolol on cAI.
In addition to these disparate effects on cAI, we could also show that irbesartan treatment preserved the natural central to peripheral amplification of SBP and PP. In contrast, atenolol led to a reduction of both the SBP and the PP gradient, again, more markedly after six months than after 18 months. These disparate effects of irbesartan versus atenolol are most likely of clinical relevance, as an attenuation of these Key: cAI = and central augmentation index; cAP = central augmentation pressure; caSBP = carotid systolic blood pressure; caDBP = Carotid diastolic blood pressure; cDBP = central diastolic blood pressure; cP1 = central pressure height 1 ; cP2 = central pressure height 2; cSBP = central systolic blood pressure; ED = ejection duration; * = p<0.05, ** = p<0.01, *** = p<0.001 compared to baseline by Bonferoni post-hoc test; Δ = respective changes from baseline. Key: SBP-Amp = systolic blood pressure amplification; PP-Amp = pulse pressure amplification; * = p<0.05, ** = p<0.01, *** = p<0.001 compared to baseline by Bonferroni post-hoc test. 
Conclusions
Our study shows that treatment of essential hypertension with irbesartan has beneficial effects on cAI and preserves central to peripheral PP amplification, whereas atenolol increases cAI and leads to an attenuation of PP amplification. These effects on haemodynamics may at least partly explain the differential effects of these drugs on cardiovascular mortality in patients with essential hypertension.
